tbuckley/cabot-search huggingface dataset:
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC).
Authors: James J. Lee, Greg Yothers, Samuel A. Jacobs, Hanna Kelly Sanoff, Deirdre Jill Cohen, Katherine A Guthrie, Norah Lynn Henry, Patricia A. Ganz, Scott Kopetz, Peter C. Lucas, Carmen Joseph Allegra, Charles David Blanke, Norman Wolmark, Howard S. Hochster, Thomas J. George, Michael J. Overman
Journal: Journal of Clinical Oncology (2019)

TPS728 Background: Deficient DNA mismatch repair (dMMR) colorectal cancer (CRC) cells are highly immunogenic. Preclinical data showed that oxaliplatin-containing chemotherapy combined with anti-VEGF enhances antitumor activity of programmed cell death-1 (PD-1) pathway blockade in murine CRC models. Prior phase I study showed mFOLFOX6/ bevacizumab (bev) + atezolizumab (atezo) was well tolerated and enhanced intratumoral infiltration of CD8 + T cells. We hypothesize that the dMMR subset of CRC may be effectively targeted with combination of PD-1 pathway blockade and mFOLFOX6/bev to promote tumor regression. Methods: This is a prospective randomized phase III open-label trial. Pts (N=347) with mCRC dMMR will be randomized to 3 trial arms (1:1:1): mFOLFOX6/bev; atezo monotherapy; or mFOLFOX6/bev + atezo. Stratification factors include BRAFV600E status, metastatic site, and prior adjuvant CRC therapy. Primary objective is to evaluate efficacy of mFOLFOX6/bev/atezo and atezo monotherapy compared to mFOLFOX6/bev. Primary endpoint is progression-free survival (PFS) assessed by study investigator. Secondary endpoints include overall survival, objective response rate, safety profile, surgical conversion rate, disease control rate, duration of response, and PFS by retrospective central review. Health-related quality of life is an exploratory objective. Archived tumor tissue and blood samples will be collected for correlative studies. Key inclusion criteria are: mCRC without prior chemotherapy for advanced disease; tumor determined to be dMMR by local CLIA-certified IHC assay (MLH1/MSH2/MSH6/PMS2); availability of archived tumor tissue for central confirmation of dMMR status; and measurable disease per RECIST. Activated 11-7-17. As of 9-24-18, 13/347 pts have been enrolled. Clinical trial: NCT02997228. Support: U10CA180868, -180822, -180888, -180819, UG1CA189867, U24CA196067; and Genentech, Inc. Clinical trial information: NCT02997228.
Malaria in an Immigrant and Travelers—Georgia, Vermont, and Tennessee, 1996
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nicotine vs placebo gum in general medical practice
Authors: J. R. Hughes
Journal: JAMA (1989)

Three hundred fifteen smokers who attended a family practice clinic and wished to quit smoking were assigned in a random, double-blind manner to receive either nicotine (2 mg) or placebo gum. Smokers initially received brief advice from a physician and nurse, a slide presentation and written materials (29 to 35 minutes), and a single follow-up visit (12 to 20 minutes) one week after cessation. After corrections for marital status and income, 10% of those who received nicotine gum and 7% of those who received placebo gum reported continuous abstinence for 11 months and passed observer and biochemical verification (this difference was not statistically significant). We conclude that, when used in a nonselected group of smokers along with a brief intervention in a general medical practice, the pharmacologic effects of nicotine gum to increase cessation are either small or nonexistent. (<i>JAMA</i>1989;261:1300-1305)
Council on Drugs. List No. 81. New names
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Journal: JAMA Psychiatry (2019)

Cognitive Behavioral Treatment for Body Dysmorphic Disorder 363About 2 of 100 individuals are affected by body dysmorphic disorder, which is associated with substantial disability and for which few treatment options are available.In this randomized clinical trial conducted at 2 sites, Wilhelm and colleagues enrolled 120 adults and compared supportive psychotherapy with cognitive behavioral therapy.Cognitive behavioral therapy worked in both sites, but supportive psychotherapy only worked in 1 site.In an Editorial, Mennin highlights the importance of examining what the patient actually adopts when engaged in therapy, which may contribute to the success for a particular disorder.Editorial 357 Continuing Medical Education jamanetwork.com/learning Nonpsychotropic Medications in Serious Mental Illness 382Drug repurposing is potentially useful, but the benefit of currently used medications for people with mental illness has not been studied.Using a population-wide registry in Sweden, Hayes and colleagues examined rates of psychiatric hospitalization and self-harm in 142 691 individuals with bipolar disorder, schizophrenia, and associated conditions and found that patients exposed to HMG-CoA reductase inhibitors, L-type calcium channel antagonists, and biguanides were significantly less likely to experience psychiatric hospitalization and self-harm.Thus, exposure to 3 classes of nonpsychotropic medications may lead to improved outcomes in serious mental illness.
Circulation Research, New York
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Official Autopsy Report on President Kennedy
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Medical Department of the University of Vermont.
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fractures and Other Bone and Joint Injuries
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Health is the loser in the vote against Europe
Authors: None The Lancet
Journal: The Lancet (2005)

While the future of Europe twists in the fetid wind created by a resounding French "Non" to the European Constitution, health policy remains a live issue all over the Union. In last month's UK election, for example, politicians waged war over multidrug resistant bacteria, waiting lists, and privatisation. In France, 3000 surgeons went on strike in May in the latest of numerous protests over the pay implications of efforts to plug an £8 billion black hole in health-sector funding. And in Germany, vehement public reactions to chancellor Gerhard Schröder's health and welfare reforms have played a large part in forcing his decision to schedule an early election, which, The Lancet has learned, might see him miss the crucial UN Millennium Development Goal summit in New York this September.
Cough mixtures
Authors: D Adler
Journal: BMJ (1978)

<b>Context</b>: In hereditary cancer syndrome families with an identified cancer associated mutation, mutation testing changes the carrier risk status of the tested person and may change the carrier risk status of relatives. <b>Objective</b>: This study aimed to describe the change in the distribution of carrier risk status resulting from testing in hereditary breast-ovarian cancer (HBOC) and hereditary non-polyposis colorectal cancer (HNPCC) families. <b>Design</b>: This was an observational cohort study. <b>Patients</b>: The cohort included members of 75 HBOC and 47 HNPCC families. Of the 10 910 cohort members, 1408 were tested for a mutation and learned their test results. <b>Outcome measure</b>: Carrier risk for all cohort members was assessed before and after mutation testing. <b>Results</b>: There was a change in carrier risk status in 2906 subjects after testing of 1408 family members. The most common type of carrier risk change, from at risk to non-carrier status, accounted for 77% of the risk changes; 12% were a change to known carrier status from a lower risk. Sixty percent of persons with a carrier risk status change were not themselves tested; their risk status changed because of a relative’s test result. <b>Conclusions</b>: Carrier risk status changes from uncertainty to certainty (that is, to carrier or to non-carrier) account for 89% of risk changes resulting from testing. These risk changes affect cancer prevention recommendations, most commonly reducing their burden. Current practices do not ensure that untested family members are informed about changes in their carrier risk status which result from mutation testing of their relatives.
Cancer Incidence among Welders: Possible Effects of Exposure to Extremely Low Frequency Electromagnetic Radiation (ELF) and to Welding Fumes
Authors: R. M. Stern
Journal: Environmental Health Perspectives (1987)

Epidemiological studies of cancer incidence among welders disclose a pooled total of 146 cases of leukemia observed versus 159.46 expected, a risk ratio of 0.92, and 40 cases of acute leukemia observed versus 43.39 expected, a risk ratio of 0.92. For respiratory tract cancer, the pooled total is 1789 cases observed versus 1290.7 expected, a risk ratio of 1.39. Most electric welders are exposed to extremely low frequency electromagnetic radiation (ELF) (magnetic flux densities of up to 100,000 microT), a suspected leukemogen, and to concentrated metallic aerosols (up to 200 mg/m3), which can contain the putative respiratory tract carcinogens Cr(VI) and Ni. The two exposures are usually coincident, since welding with an electric current produces welding fumes. The observation of an excess risk for respiratory tract cancer strongly suggests significant exposure both to fumes and to ELF. The absence of increased risk for all leukemia or for acute leukemia among ELF-exposed welders does not support the hypothesis that the observed excess risk for leukemia or acute leukemia among workers in the electrical trades is due to their ELF exposure, which on the average is lower than that of welders.
Letter Rules and Reminders
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Carcinoma erysipeloides
Authors: L. R. LEVER, P. J. A. HOLT
Journal: British Journal of Dermatology (1991)

We report an 83‐year‐old woman with carcinoma erysipeloides due to an occult carcinoma. Immunohistochemical study of skin biopsies showed reactivity to S‐100 protein and human milk fat globule antigen indicating that the tumour originated in the breast.
SELECTIONS.
Authors: C. P. Pinckard
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Triprolidine.
Authors: L. J. A. Loewenthal
Journal: British Journal of Dermatology (1964)

Journal Article Triprolidine. Get access L. J. A. Loewenthal L. J. A. Loewenthal Johannesburg Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 76, Issue 8-9, 1 August 1964, Page 398, https://doi.org/10.1111/j.1365-2133.1964.tb14554.x Published: 01 August 1964
Inflammation-mediator blockers may be weapons against sepsis syndrome
Authors: A. Skolnick
Journal: JAMA (1990)

SEPSIS SYNDROME or septic shock, a frequently fatal inflammatory response to infections involving endotoxin-producing gram-negative bacteria and sometimes other organisms, affects many thousands of people in the United States each year. In more than 50% of cases, sepsis syndrome leads to major organ damage, and, depending on the patient population studied, from 20% to 90% die, despite all medical efforts. Any major organ may be affected, although the lungs often take the brunt of the damage. According to a 1972 estimate by the National Heart, Lung, and Blood Institute Lung Program, approximately 150 000 patients each year develop adult respiratory distress syndrome (ARDS). While the number of cases occurring today is unknown, the fatality rate, which is 50% to 70%, has remained about the same, as best can be determined. <h3>Sepsis Symptoms</h3> The symptoms of sepsis syndrome usually include fever, chills, lethargy, hypotension, tachycardia, hyperventilation, thrombosis, and leukocytosis. Sepsis-induced lung
Microelimination beyond prison walls: subjects sentenced to non-custodial sentences, screening and immediate assisted treatment with “navigator” figure and telemedicine
Authors: Susana Llerena, Joaquin Cabezas, Miguel Mateo, Rocio Alvarez, Maria del Mar Fernandez, Carmen Cobo, Antonio Cuadrado, Javier Crespo
Journal: Journal of Hepatology (2020)
Attempting to reduce hospital costs by strengthening primary care institutions. The Dutch Health Care Demonstration Project in the new town of Almere
Authors: H. J. Sixma
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Missing Affiliation
Authors: John Zic, Jami Miller, ; Arbuckle, Linnea Hemphill, Mayumi Fujita, David Norris, Preethi Ramaswamy, Jennifer Nevas, Caroline Rao, Allen Gifford, Kelly Asher, Adela Rambi, G Cardones, Angela Richardson, Carmen Patrick, Louis Fiore, Ryan Ferguson, ; Soe, Soe Thwin, Denis Rybin, Robert Lew, Clara Kebabian, Jennifer Pavao, Mike Sather, Carol Fye, Robert Ringer, David Hunt, Leslie Robinson-Bostom, Gladys Telang, Caroline Wilkel, Safety Monitoring, Harley Haynes, Maurice Brookhart, Eliot Mostow, Thomas Rector
Journal: JAMA Dermatology (2018)

Elisabeth Castellanos, PhD; Adrià Plana, MD; Cristina Carrato, MD, PhD; Meritxell Carrió, PhD; Inma Rosas, LT; Emilio Amilibia, MD; Francesc Roca-Ribas, MD, PhD; Cristina Hostalot, MD; Alicia Castillo, BN; Andrea Ros, BS; Ariadna Quer, MD; Juan Luis Becerra, MD; Hector Salvador, MD; Conxi Lázaro, PhD; Ignacio Blanco, MD, PhD; Eduard Serra, PhD; Isabel Bielsa, MD, PhD; for CSUR Phakomatoses Multidisciplinary Clinics HUGTiP-ICO-IGTP